An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g

Trial Profile

An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms VOYAGER
  • Sponsors Genentech
  • Most Recent Events

    • 22 Dec 2009 Primary outcome amended as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Actual end date (July 2008) added as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Actual patient number (31) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top